Coeptis Therapeutics Secures $4.3M in Series A Preferred Offering

Coeptis Therapeutics Holdings, Inc. has successfully secured $4.3 million through a financing round led by CJC Investment Trust, an entity controlled by Christopher Calise, a board member. This financing was structured as a Series A Preferred stock offering, convertible into common stock at $0.40 per share. Additionally, investors received a 6.45% equity stake in Coeptis’ newly established subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics Inc.

Dave Mehalick, President and CEO of Coeptis, expressed gratitude for the investors' support, emphasizing their shared long-term vision for the company. He noted that the financing arrives at a crucial time as Coeptis anticipates several significant milestones in the near future. This investment not only strengthens the company's financial position but also enhances its cell therapy platforms and long-term growth prospects.

The funds will be used for debt repayment, working capital, and general corporate purposes.

Coeptis Therapeutics Holdings, Inc., headquartered in Wexford, PA, is a biopharmaceutical company focused on innovative cell therapy platforms targeting cancer, autoimmune, and infectious diseases. The company’s product portfolio includes assets licensed from Deverra Therapeutics, such as an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage unmodified natural killer cell therapy. Coeptis is also developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and researchers at the Karolinska Institutet.

Coeptis aims to maximize the value of its product portfolio through in-license agreements, out-license agreements, and strategic partnerships, particularly focusing on cancer and infectious diseases. The company’s business model leverages these partnerships to expand its product rights and offerings.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!